Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Meyer Handelman Co.

Meyer Handelman Co. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 365,524 shares of the biopharmaceutical company's stock after selling 3,655 shares during the quarter. Gilead Sciences comprises approximately 1.4% of Meyer Handelman Co.'s investment portfolio, making the stock its 18th biggest holding. Meyer Handelman Co.'s holdings in Gilead Sciences were worth $40,957,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. HHM Wealth Advisors LLC grew its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $28,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $31,000. Stephens Consulting LLC lifted its stake in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 260 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the sale, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at approximately $17,893,713.60. The trade was a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 60,929 shares of company stock valued at $6,748,980 in the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of GILD stock traded up $0.42 during mid-day trading on Tuesday, hitting $109.33. 9,875,048 shares of the stock were exchanged, compared to its average volume of 7,732,448. The firm has a fifty day moving average of $105.49 and a 200 day moving average of $101.04. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96. The company has a market cap of $136.00 billion, a PE ratio of 295.49, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the company posted ($1.32) EPS. The company's revenue for the quarter was down .3% on a year-over-year basis. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.89%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on GILD shares. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Piper Sandler lifted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.